Intas and IntegriMedical to launch India’s first needle-free injection system for IVF and gynaecology
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Subscribe To Our Newsletter & Stay Updated